论文部分内容阅读
目的：分析ＥＢ病毒血清学ＶＣＡ－ＩｇＡ抗体与鼻咽癌病人远期疗效关系，为临床治疗提供参考依据。方法：１９８５年本院病理确诊的５２２例鼻咽癌病人，按治疗前、后ＶＣＡ－ＩｇＡ抗体滴度分为三组：低滴度组（１：５～１：２０）、中滴度组（１：４０～１：８０）和高滴度组（１：１６０以上），随访１０年，比较生存率的异同。结果：治疗前鼻咽癌病人高滴度组１０年生存率低于低滴度组（Ｐ＜０．０５），但和中滴度组差别无显著性（Ｐ＞０．０５）。治疗后三组病人１０年生存率比较，高、中滴度二组差别无显著性（Ｐ＞０．０５），但低于低滴度组。结论：ＥＢ病毒ＶＣＡ－ＩｇＡ抗体水平可以作为估计预后的重要参考依据，与远期疗效有密切关系。
OBJECTIVE: To analyze the long-term efficacy of Epstein-Barr virus serological VCA-IgA antibody in patients with nasopharyngeal carcinoma and to provide a reference for clinical treatment. Methods: A total of 522 nasopharyngeal carcinoma patients diagnosed in our hospital in 1985 were divided into three groups according to the titer of VCA-IgA before and after treatment: low titer group (1: 5-1: 20), middle titer group (1:40 ~ 1:80) and high titer group (1: 160 or more), followed up for 10 years, comparing the similarities and differences of survival rate. Results: The 10-year survival rate of patients with high-titer nasopharyngeal carcinoma before treatment was lower than that of low-titer patients (P <0.05), but there was no significant difference between the two groups (P> 0.05). After treatment, the 10-year survival rate of three groups of patients was no significant difference (P> 0.05), but lower than the low titer group. Conclusion: The level of VCA-IgA antibody of Epstein-Barr virus can be used as an important reference for estimating prognosis, which is closely related to long-term efficacy.